Health Care·Biotechnology·$3.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.25 | N/A | -20.77% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.25 | N/A | -20.77% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious approach, emphasizing the importance of their clinical pipeline. They did not offer specific guidance for future quarters.
Management did not provide specific guidance for future performance.
The company is focused on ongoing clinical trials and product development.
This earnings report indicates that ACADIA Pharmaceuticals is still in a challenging phase, as reflected by the EPS miss. However, the stock rose by 1.88%, suggesting that investors may be optimistic about the company's long-term potential despite the current losses. The lack of revenue data and guidance may keep some investors cautious.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
NEXSTAR MEDIA GROUP Class A
Nov 7, 2014